middle.news

Neuren Publishes Promising Phase 2 Data as Phase 3 Koala Trial Recruits PMS Patients

10:42am on Wednesday 7th of January, 2026 AEDT Healthcare
Read Story

Neuren Publishes Promising Phase 2 Data as Phase 3 Koala Trial Recruits PMS Patients

10:42am on Wednesday 7th of January, 2026 AEDT
Key Points
  • Phase 2 trial results published in Neurology® Genetics
  • NNZ-2591 well-tolerated with meaningful symptom improvements
  • Phase 3 Koala trial recruiting children aged 3 to 12 in the US
  • FDA granted Fast Track, Rare Pediatric Disease, and Orphan Drug designations
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE